He S, Wang X Y, Han Q Y, Liu Z W
Department of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China Xi'an Medical University, Xi'an 710021, China.
Department of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Zhonghua Gan Zang Bing Za Zhi. 2021 Jan 20;29(1):83-86. doi: 10.3760/cma.j.cn501113-20190606-00199.
Sofosbuvir has ushered in a new era of hepatitis C treatment with its strong inhibition on the replication of hepatitis C virus, favorable safety profile and less interactions with other drugs. Sofosbuvir-based regimens have been included as the first-line therapies for the treatment of adults with chronic hepatitis C (CHC) in international guidelines. Available clinical trial data show that sofosbuvir with ribavirin and ledipasvir/sofosbuvir are highly efficacious and safe in CHC patients aged 3-17 years old; therefore, they can meet the unmet medical needs of adolescents and children with CHC in China. Furthermore, the pan-genotypic sofosbuvir/velpatasvir is being investigated in adolescents and children with CHC, which is expected to make the treatment in such patients more convenient upon approval.
索磷布韦对丙型肝炎病毒复制具有强大抑制作用、安全性良好且与其他药物相互作用较少，从而开创了丙型肝炎治疗的新时代。基于索磷布韦的治疗方案已被纳入国际指南中作为治疗成人慢性丙型肝炎（CHC）的一线疗法。现有临床试验数据表明，索磷布韦联合利巴韦林以及来迪派韦/索磷布韦在3至17岁的CHC患者中具有高度有效性和安全性；因此，它们能够满足中国CHC青少年和儿童尚未满足的医疗需求。此外，泛基因型的索磷布韦/维帕他韦正在CHC青少年和儿童中进行研究，有望在获批后使此类患者的治疗更加便捷。
